聯瑞新材(688300.SH):擬以2.5億元向連雲港聯瑞增資 用於其年產15000噸高端芯片封裝用球形粉體生產線建設項目等
格隆匯11月14日丨聯瑞新材(688300.SH)公佈,公司於2021年11月12日召開了第三屆董事會第十一次會議,審議通過了《關於向全資子公司增資的議案》,同意使用自有資金2.5億元人民幣向全資子公司聯瑞新材(連雲港)有限公司(“連雲港聯瑞”)進行增資,用於連雲港聯瑞投資年產15000噸高端芯片封裝用球形粉體生產線建設項目等項目的建設和運營。
此次向連雲港聯瑞增資將增加其註冊資本,增資事項完成後,連雲港聯瑞的註冊資本將由1億元人民幣增至3.5億元人民幣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.